Related Experiment Video

Updated: Jul 16, 2026

Time-resolved Förster Resonance Energy Transfer Assays for Measurement of Endogenous Phosphorylated STAT Proteins in Human Cells
07:12

Time-resolved Förster Resonance Energy Transfer Assays for Measurement of Endogenous Phosphorylated STAT Proteins in Human Cells

Published on: September 9, 2021

Targeting of Jak/STAT pathway in antigen presenting cells in cancer

Yulia Nefedova1, Dmitry I Gabrilovich

  • 1H. Lee Moffitt Cancer Center, University of South Florida, Tampa, FL 33612, USA.

Current Cancer Drug Targets
|February 20, 2007
PubMed

Insights

Tumor cells can evade immune detection by impairing dendritic cells (DCs), the key antigen-presenting cells (APCs). This review explores how Signal Transducers and Activators of Transcription (STATs), particularly STAT3, contribute to these defects and discusses potential therapies.

Area of Science:

  • Immunology
  • Oncology
  • Molecular Biology

Background:

  • Tumor cells escape immune surveillance through various mechanisms.
  • A critical mechanism involves defects in antigen-presenting cells (APCs), especially dendritic cells (DCs).
  • Tumor-derived factors are implicated in causing these APC defects.

Purpose of the Study:

  • To review recent findings on the role of Signal Transducers and Activators of Transcription (STATs) in cancer.
  • To specifically investigate the involvement of STAT3 in abnormal dendritic cell differentiation and function in cancer.
  • To discuss pharmacological strategies targeting the STAT pathway for enhancing antitumor immunity.

Main Methods:

  • Literature review of recent research findings.
  • Analysis of the role of STAT family members, focusing on STAT3.
  • Discussion of therapeutic approaches targeting STAT signaling.

Main Results:

  • Evidence suggests STATs, particularly STAT3, are implicated in impaired dendritic cell differentiation and function in cancer.
  • Dysfunctional dendritic cells fail to elicit a potent antitumor immune response.
  • Pharmacological regulation of the STAT pathway shows potential for restoring DC function.

Conclusions:

  • STAT3 plays a significant role in cancer-induced immune evasion by disrupting dendritic cell function.
  • Targeting STAT signaling represents a promising strategy to enhance DC-mediated antitumor immunity.
  • Further research into STAT pathway modulation could lead to novel cancer immunotherapies.

More Related Videos

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

Related Concept Videos

The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...